item 2 . properties . we conduct our primary operations at the owned and leased facilities described below . location operations conducted approximate square feet expiration new haven , connecticut corporate headquarters and executive , sales , research and development offices 514000 .

Table:
location | operations conducted | approximatesquare feet | leaseexpirationdates
new haven connecticut | corporate headquarters and executive sales research and development offices | 514000 | 2030
dublin ireland | global supply chain distribution and administration offices | 215000 | owned
lexington massachusetts | research and development offices | 81000 | 2019
bogart georgia | commercial research and development manufacturing | 70000 | 2024
smithfield rhode island | commercial research and development manufacturing | 67000 | owned
zurich switzerland | regional executive and sales offices | 69000 | 2025
we believe that our administrative office space is adequate to meet our needs for the foreseeable future .
we also believe that our research and development facilities and our manufacturing facility , together with third party manufacturing facilities , will be adequate for our on-going activities .
in addition to the locations above , we also lease space in other u.s .
locations and in foreign countries to support our operations as a global organization .
as of december 31 , 2015 , we also leased approximately 254000 square feet in cheshire , connecticut , which was the previous location of our corporate headquarters and executive , sales , research and development offices .
in december 2015 , we entered into an early termination of this lease and will occupy this space through may 2016 .
in april 2014 , we purchased a fill/finish facility in athlone , ireland .
following refurbishment of the facility , and after successful completion of the appropriate validation processes and regulatory approvals , the facility will become our first company-owned fill/finish and packaging facility for our commercial and clinical products .
in may 2015 , we announced plans to construct a new biologics manufacturing facility on our existing property in dublin ireland , which is expected to be completed by 2020 .
item 3 .
legal proceedings .
in may 2015 , we received a subpoena in connection with an investigation by the enforcement division of the sec requesting information related to our grant-making activities and compliance with the fcpa in various countries .
the sec also seeks information related to alexion 2019s recalls of specific lots of soliris and related securities disclosures .
in addition , in october 2015 , alexion received a request from the doj for the voluntary production of documents and other information pertaining to alexion's compliance with the fcpa .
alexion is cooperating with these investigations .
at this time , alexion is unable to predict the duration , scope or outcome of these investigations .
given the ongoing nature of these investigations , management does not currently believe a loss related to these matters is probable or that the potential magnitude of such loss or range of loss , if any , can be reasonably estimated .
item 4 .
mine safety disclosures .
not applicable. .

Question: how many square feet are leased by alexion pharmaceuticals , inc?
Answer: 734000
Calculation: add(514000, 81000), add(#0, 70000), add(#1, 69000)